Whooping cough, or pertussis, cases are spiking across the US and Europe. Experts say it’s unclear why. In the winter of 2023, health experts across the European continent started noticing something ...

Humacyte's stock price has recently been on an impressive bull run. Read why I could see HUMA achieving a billion-dollar ...

Human Acellular Vessel (HAV). The U.S. regulator accepted Humacyte’s (HUMA) biologics license application for HAV early this ...

Among 310 pregnancies in women living with HIV, the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) ...

The Department of Public Health and Social Services is advising travelers to stay up to date with their vaccinations as ...

Financial Outlook: Expects current cash reserves to fund operations for at least 12 months, aligning with anticipated timelines for FDA approval of HAV in vascular trauma.

A panel of female medical professionals will discuss the clinical evidence of Kerecis’ products in surgical and outpatient ...

Another key change, says Dr. Hunter, is the shift in the early 2010s from a whole-cell to an acellular vaccine for whooping ...

Several randomized pertussis vaccine efficacy studies were conducted in Europe and Africa to compare the safety and efficacy of the acellular and the whole-cell pertussis vaccines for the ...